Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare
Free Samples
Cancer

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1404015

Cover Image

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1404015

Actinic Keratosis Treatment Market - Global Industry Analysis, Size, Share, Growth, Trends, & Forecast 2031 - By Product, Technology, Grade, Application, End-user, Region: (North America, Europe, Asia Pacific, Latin America & Middle East & Africa)

PUBLISHED:
PAGES: 275 Pages
DELIVERY TIME: 2-5 business days
REQUEST FREE SAMPLE
REQUEST CUSTOMIZATION
SELECT AN OPTION
Unprintable PDF & Excel (Single User License)
USD 4995
Unprintable PDF & Excel (Multi User License upto 5 users)
USD 8495
Printable PDF & Excel (Enterprise License above 5 users)
USD 10600

Add to Cart

Description

Table of Contents

The global Actinic Keratosis Treatment Market is on the path to significant growth during forecast period. In 2024, the global Actinic Keratosis Treatment Market reached a substantial size of US$ 6 billion and is expected to further expand to US$ 9.5 million by the year 2031.

Factors Driving Growth in the Actinic Keratosis Treatment Market

  • Rise in the Prevalence of Actinic Keratosis: The increasing prevalence of actinic keratosis, coupled with growing awareness of the disease and a rising demand for minimally invasive therapies, is expected to drive the growth of the actinic keratosis treatment market. As awareness about the harmful effects of actinic keratosis grows, the need for effective treatments is on the rise. Government agencies and non-profit organizations running awareness programs contribute significantly to market development. Increased research and development initiatives are also set to boost the approval of new medications for actinic keratosis treatment. Moreover, the heightened risk of developing skin cancer related to actinic keratosis has increased detection and treatment rates.
  • Increase in Drug Approvals and Novel Therapies: The market is expected to grow due to the increasing number of drug approvals and the introduction of novel medications for actinic keratosis. The US Food and Drug Administration (FDA) has approved new drugs for actinic keratosis treatment, including topical fluorouracil, imiquimod, diclofenac, ingenol mebutate, and pharmaceutical treatment combinations. Topical medications hold a significant market share due to their ease of availability, high target specificity, and lower risk of scarring. The approval of novel medications and the utilization of combination treatments are expected to drive market growth further. Increased research and development efforts are also likely to result in the approval of new drugs, boosting the Actinic Keratosis Treatment Market.

Challenges Facing the Actinic Keratosis Treatment Market

"Lack of Skilled Professionals and Limited Treatment Penetration": The primary challenges hindering market growth include a shortage of skilled professionals and limited treatment penetration in emerging economies. Actinic keratosis treatment necessitates skilled professionals and surgeons for procedures such as chemical peels, cryotherapy, and photodynamic therapy. However, a significant shortage of general surgeons is expected to impede market growth. Additionally, limited awareness of the health problem in developing countries and high treatment costs are projected to restrict market expansion. The emergence of alternative natural remedies may also pose a challenge to the market.

Impact of COVID-19 on the Actinic Keratosis Treatment Market

"Drop in Sales Due to Lockdown": The COVID-19 pandemic had adverse effects on the global economy and impacted various industries due to travel restrictions, lockdowns, and business closures. Supply chain disruptions for medical equipment, caused by the lockdowns, led to a decline in sales in the actinic keratosis treatment market in 2020. Strict lockdown measures prompted many doctors to adopt telemedicine, resulting in a significant decrease in detection and treatment rates. While the pandemic significantly affected the Actinic Keratosis Treatment Market, conditions have begun to improve since September 2021.

Competitive Landscape

The Actinic Keratosis Treatment industry is highly competitive and consolidated, with a few key players dominating the market. These companies are strategically focusing on mergers and alliances to capitalize on the industry's growth phase. New product launches are also on their agenda to expand market share.

Key Companies Profiled

  • Sun Pharmaceutical Industries Ltd.
  • Biofrontera
  • Nestle SA
  • Bausch Health Companies Inc.
  • Novartis AG
  • GlaxoSmithKline plc.
  • Almirall, LLC
  • LEO Pharma Inc.
  • Cipher Pharmaceuticals Inc.
  • Pierre Fabre Pharmaceuticals, Inc.

Actinic Keratosis Treatment Market Categorization

Actinic Keratosis Treatment Market by End User

  • Hospitals
  • Private Dermatology Clinics
  • Laser Therapy Centers
  • Cancer Treatment Centers
  • Spas and Rejuvenation Centers
  • Homecare

Actinic Keratosis Treatment Market by Region

  • North America
  • Latin America
  • Europe
  • Asia Pacific
  • Middle East & Africa (MEA)
Show more

Table of Contents

1. Executive Summary

  • 1.1. Global Actinic Keratosis Treatment Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2023
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. COVID-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Actinic Keratosis Treatment Market Outlook, 2018 - 2031

  • 3.1. Global Actinic Keratosis Treatment Market Outlook, by Treatment Type, Value (US$ Mn), 2018 - 2031
    • 3.1.1. Key Highlights
      • 3.1.1.1. Topical Treatment
        • 3.1.1.1.1. 5-fluorouracil Cream
        • 3.1.1.1.2. Diclofenac Ge
        • 3.1.1.1.3. Imiquimod Cream
        • 3.1.1.1.4. Ingenol Mebutate Gel
      • 3.1.1.2. Procedural Modality
        • 3.1.1.2.1. Chemical Peels
        • 3.1.1.2.2. Cryotherapy
      • 3.1.1.3. Photodynamic Therapy
      • 3.1.1.4. Others
  • 3.2. Global Actinic Keratosis Treatment Market Outlook, by Disease Type, Value (US$ Mn), 2018 - 2031
    • 3.2.1. Key Highlights
      • 3.2.1.1. Clinical AK
      • 3.2.1.2. Subclinical AK
  • 3.3. Global Actinic Keratosis Treatment Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
    • 3.3.1. Key Highlights
      • 3.3.1.1. Hospitals
      • 3.3.1.2. Private Dermatology Clinic
      • 3.3.1.3. Laser Therapy Centers
      • 3.3.1.4. Cancer Treatment Centers
      • 3.3.1.5. Spas and Rejuvenation Centers
      • 3.3.1.6. Homecare
  • 3.4. Global Actinic Keratosis Treatment Market Outlook, by Region, Value (US$ Mn), 2018 - 2031
    • 3.4.1. Key Highlights
      • 3.4.1.1. North America
      • 3.4.1.2. Europe
      • 3.4.1.3. Asia Pacific
      • 3.4.1.4. Latin America
      • 3.4.1.5. Middle East & Africa

4. North America Actinic Keratosis Treatment Market Outlook, 2018 - 2031

  • 4.1. North America Actinic Keratosis Treatment Market Outlook, by Treatment Type, Value (US$ Mn), 2018 - 2031
    • 4.1.1. Key Highlights
      • 4.1.1.1. Topical Treatment
        • 4.1.1.1.1. 5-fluorouracil Cream
        • 4.1.1.1.2. Diclofenac Ge
        • 4.1.1.1.3. Imiquimod Cream
        • 4.1.1.1.4. Ingenol Mebutate Gel
      • 4.1.1.2. Procedural Modality
        • 4.1.1.2.1. Chemical Peels
        • 4.1.1.2.2. Cryotherapy
      • 4.1.1.3. Photodynamic Therapy
      • 4.1.1.4. Others
  • 4.2. North America Actinic Keratosis Treatment Market Outlook, by Disease Type, Value (US$ Mn), 2018 - 2031
    • 4.2.1. Key Highlights
      • 4.2.1.1. Clinical AK
      • 4.2.1.2. Subclinical AK
  • 4.3. North America Actinic Keratosis Treatment Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
    • 4.3.1. Key Highlights
      • 4.3.1.1. Hospitals
      • 4.3.1.2. Private Dermatology Clinic
      • 4.3.1.3. Laser Therapy Centers
      • 4.3.1.4. Cancer Treatment Centers
      • 4.3.1.5. Spas and Rejuvenation Centers
      • 4.3.1.6. Homecare
    • 4.3.2. BPS Analysis/Market Attractiveness Analysis
  • 4.4. North America Actinic Keratosis Treatment Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 4.4.1. Key Highlights
      • 4.4.1.1. U.S. Actinic Keratosis Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 4.4.1.2. U.S. Actinic Keratosis Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
      • 4.4.1.3. U.S. Actinic Keratosis Treatment Market by End User, Value (US$ Mn), 2018 - 2031
      • 4.4.1.4. Canada Actinic Keratosis Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 4.4.1.5. Canada Actinic Keratosis Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
      • 4.4.1.6. Canada Actinic Keratosis Treatment Market by End User, Value (US$ Mn), 2018 - 2031
    • 4.4.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Actinic Keratosis Treatment Market Outlook, 2018 - 2031

  • 5.1. Europe Actinic Keratosis Treatment Market Outlook, by Treatment Type, Value (US$ Mn), 2018 - 2031
    • 5.1.1. Key Highlights
      • 5.1.1.1. Topical Treatment
        • 5.1.1.1.1. 5-fluorouracil Cream
        • 5.1.1.1.2. Diclofenac Ge
        • 5.1.1.1.3. Imiquimod Cream
        • 5.1.1.1.4. Ingenol Mebutate Gel
      • 5.1.1.2. Procedural Modality
        • 5.1.1.2.1. Chemical Peels
        • 5.1.1.2.2. Cryotherapy
      • 5.1.1.3. Photodynamic Therapy
      • 5.1.1.4. Others
  • 5.2. Europe Actinic Keratosis Treatment Market Outlook, by Disease Type, Value (US$ Mn), 2018 - 2031
    • 5.2.1. Key Highlights
      • 5.2.1.1. Clinical AK
      • 5.2.1.2. Subclinical AK
  • 5.3. Europe Actinic Keratosis Treatment Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
    • 5.3.1. Key Highlights
      • 5.3.1.1. Hospitals
      • 5.3.1.2. Private Dermatology Clinic
      • 5.3.1.3. Laser Therapy Centers
      • 5.3.1.4. Cancer Treatment Centers
      • 5.3.1.5. Spas and Rejuvenation Centers
      • 5.3.1.6. Homecare
    • 5.3.2. BPS Analysis/Market Attractiveness Analysis
  • 5.4. Europe Actinic Keratosis Treatment Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 5.4.1. Key Highlights
      • 5.4.1.1. Germany Actinic Keratosis Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 5.4.1.2. Germany Actinic Keratosis Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
      • 5.4.1.3. Germany Actinic Keratosis Treatment Market by End User, Value (US$ Mn), 2018 - 2031
      • 5.4.1.4. U.K. Actinic Keratosis Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 5.4.1.5. U.K. Actinic Keratosis Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
      • 5.4.1.6. U.K. Actinic Keratosis Treatment Market by End User, Value (US$ Mn), 2018 - 2031
      • 5.4.1.7. France Actinic Keratosis Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 5.4.1.8. France Actinic Keratosis Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
      • 5.4.1.9. France Actinic Keratosis Treatment Market by End User, Value (US$ Mn), 2018 - 2031
      • 5.4.1.10. Italy Actinic Keratosis Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 5.4.1.11. Italy Actinic Keratosis Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
      • 5.4.1.12. Italy Actinic Keratosis Treatment Market by End User, Value (US$ Mn), 2018 - 2031
      • 5.4.1.13. Turkey Actinic Keratosis Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 5.4.1.14. Turkey Actinic Keratosis Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
      • 5.4.1.15. Turkey Actinic Keratosis Treatment Market by End User, Value (US$ Mn), 2018 - 2031
      • 5.4.1.16. Russia Actinic Keratosis Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 5.4.1.17. Russia Actinic Keratosis Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
      • 5.4.1.18. Russia Actinic Keratosis Treatment Market by End User, Value (US$ Mn), 2018 - 2031
      • 5.4.1.19. Rest of Europe Actinic Keratosis Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 5.4.1.20. Rest of Europe Actinic Keratosis Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
      • 5.4.1.21. Rest of Europe Actinic Keratosis Treatment Market by End User, Value (US$ Mn), 2018 - 2031
    • 5.4.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Actinic Keratosis Treatment Market Outlook, 2018 - 2031

  • 6.1. Asia Pacific Actinic Keratosis Treatment Market Outlook, by Treatment Type, Value (US$ Mn), 2018 - 2031
    • 6.1.1. Key Highlights
      • 6.1.1.1. Topical Treatment
        • 6.1.1.1.1. 5-fluorouracil Cream
        • 6.1.1.1.2. Diclofenac Ge
        • 6.1.1.1.3. Imiquimod Cream
        • 6.1.1.1.4. Ingenol Mebutate Gel
      • 6.1.1.2. Procedural Modality
        • 6.1.1.2.1. Chemical Peels
        • 6.1.1.2.2. Cryotherapy
      • 6.1.1.3. Photodynamic Therapy
      • 6.1.1.4. Others
  • 6.2. Asia Pacific Actinic Keratosis Treatment Market Outlook, by Disease Type, Value (US$ Mn), 2018 - 2031
    • 6.2.1. Key Highlights
      • 6.2.1.1. Clinical AK
      • 6.2.1.2. Subclinical AK
  • 6.3. Asia Pacific Actinic Keratosis Treatment Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
    • 6.3.1. Key Highlights
      • 6.3.1.1. Hospitals
      • 6.3.1.2. Private Dermatology Clinic
      • 6.3.1.3. Laser Therapy Centers
      • 6.3.1.4. Cancer Treatment Centers
      • 6.3.1.5. Spas and Rejuvenation Centers
      • 6.3.1.6. Homecare
    • 6.3.2. BPS Analysis/Market Attractiveness Analysis
  • 6.4. Asia Pacific Actinic Keratosis Treatment Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 6.4.1. Key Highlights
      • 6.4.1.1. China Actinic Keratosis Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 6.4.1.2. China Actinic Keratosis Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
      • 6.4.1.3. China Actinic Keratosis Treatment Market by End User, Value (US$ Mn), 2018 - 2031
      • 6.4.1.4. Japan Actinic Keratosis Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 6.4.1.5. Japan Actinic Keratosis Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
      • 6.4.1.6. Japan Actinic Keratosis Treatment Market by End User, Value (US$ Mn), 2018 - 2031
      • 6.4.1.7. South Korea Actinic Keratosis Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 6.4.1.8. South Korea Actinic Keratosis Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
      • 6.4.1.9. South Korea Actinic Keratosis Treatment Market by End User, Value (US$ Mn), 2018 - 2031
      • 6.4.1.10. India Actinic Keratosis Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 6.4.1.11. India Actinic Keratosis Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
      • 6.4.1.12. India Actinic Keratosis Treatment Market by End User, Value (US$ Mn), 2018 - 2031
      • 6.4.1.13. Southeast Asia Actinic Keratosis Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 6.4.1.14. Southeast Asia Actinic Keratosis Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
      • 6.4.1.15. Southeast Asia Actinic Keratosis Treatment Market by End User, Value (US$ Mn), 2018 - 2031
      • 6.4.1.16. Rest of Asia Pacific Actinic Keratosis Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 6.4.1.17. Rest of Asia Pacific Actinic Keratosis Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
      • 6.4.1.18. Rest of Asia Pacific Actinic Keratosis Treatment Market by End User, Value (US$ Mn), 2018 - 2031
    • 6.4.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Actinic Keratosis Treatment Market Outlook, 2018 - 2031

  • 7.1. Latin America Actinic Keratosis Treatment Market Outlook, by Treatment Type, Value (US$ Mn), 2018 - 2031
    • 7.1.1. Key Highlights
      • 7.1.1.1. Topical Treatment
        • 7.1.1.1.1. 5-fluorouracil Cream
        • 7.1.1.1.2. Diclofenac Ge
        • 7.1.1.1.3. Imiquimod Cream
        • 7.1.1.1.4. Ingenol Mebutate Gel
      • 7.1.1.2. Procedural Modality
        • 7.1.1.2.1. Chemical Peels
        • 7.1.1.2.2. Cryotherapy
      • 7.1.1.3. Photodynamic Therapy
      • 7.1.1.4. Others
  • 7.2. Latin America Actinic Keratosis Treatment Market Outlook, by Disease Type, Value (US$ Mn), 2018 - 2031
    • 7.2.1. Key Highlights
      • 7.2.1.1. Clinical AK
      • 7.2.1.2. Subclinical AK
  • 7.3. Latin America Actinic Keratosis Treatment Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
    • 7.3.1. Key Highlights
      • 7.3.1.1. Hospitals
      • 7.3.1.2. Private Dermatology Clinic
      • 7.3.1.3. Laser Therapy Centers
      • 7.3.1.4. Cancer Treatment Centers
      • 7.3.1.5. Spas and Rejuvenation Centers
      • 7.3.1.6. Homecare
    • 7.3.2. BPS Analysis/Market Attractiveness Analysis
  • 7.4. Latin America Actinic Keratosis Treatment Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 7.4.1. Key Highlights
      • 7.4.1.1. Brazil Actinic Keratosis Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 7.4.1.2. Brazil Actinic Keratosis Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
      • 7.4.1.3. Brazil Actinic Keratosis Treatment Market by End User, Value (US$ Mn), 2018 - 2031
      • 7.4.1.4. Mexico Actinic Keratosis Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 7.4.1.5. Mexico Actinic Keratosis Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
      • 7.4.1.6. Mexico Actinic Keratosis Treatment Market by End User, Value (US$ Mn), 2018 - 2031
      • 7.4.1.7. Argentina Actinic Keratosis Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 7.4.1.8. Argentina Actinic Keratosis Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
      • 7.4.1.9. Argentina Actinic Keratosis Treatment Market by End User, Value (US$ Mn), 2018 - 2031
      • 7.4.1.10. Rest of Latin America Actinic Keratosis Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 7.4.1.11. Rest of Latin America Actinic Keratosis Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
      • 7.4.1.12. Rest of Latin America Actinic Keratosis Treatment Market by End User, Value (US$ Mn), 2018 - 2031
    • 7.4.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Actinic Keratosis Treatment Market Outlook, 2018 - 2031

  • 8.1. Middle East & Africa Actinic Keratosis Treatment Market Outlook, by Treatment Type, Value (US$ Mn), 2018 - 2031
    • 8.1.1. Key Highlights
      • 8.1.1.1. Topical Treatment
        • 8.1.1.1.1. 5-fluorouracil Cream
        • 8.1.1.1.2. Diclofenac Ge
        • 8.1.1.1.3. Imiquimod Cream
        • 8.1.1.1.4. Ingenol Mebutate Gel
      • 8.1.1.2. Procedural Modality
        • 8.1.1.2.1. Chemical Peels
        • 8.1.1.2.2. Cryotherapy
      • 8.1.1.3. Photodynamic Therapy
      • 8.1.1.4. Others
  • 8.2. Middle East & Africa Actinic Keratosis Treatment Market Outlook, by Disease Type, Value (US$ Mn), 2018 - 2031
    • 8.2.1. Key Highlights
      • 8.2.1.1. Clinical AK
      • 8.2.1.2. Subclinical AK
  • 8.3. Middle East & Africa Actinic Keratosis Treatment Market Outlook, by End User, Value (US$ Mn), 2018 - 2031
    • 8.3.1. Key Highlights
      • 8.3.1.1. Hospitals
      • 8.3.1.2. Private Dermatology Clinic
      • 8.3.1.3. Laser Therapy Centers
      • 8.3.1.4. Cancer Treatment Centers
      • 8.3.1.5. Spas and Rejuvenation Centers
      • 8.3.1.6. Homecare
    • 8.3.2. BPS Analysis/Market Attractiveness Analysis
  • 8.4. Middle East & Africa Actinic Keratosis Treatment Market Outlook, by Country, Value (US$ Mn), 2018 - 2031
    • 8.4.1. Key Highlights
      • 8.4.1.1. GCC Actinic Keratosis Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 8.4.1.2. GCC Actinic Keratosis Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
      • 8.4.1.3. GCC Actinic Keratosis Treatment Market by End User, Value (US$ Mn), 2018 - 2031
      • 8.4.1.4. South Africa Actinic Keratosis Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 8.4.1.5. South Africa Actinic Keratosis Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
      • 8.4.1.6. South Africa Actinic Keratosis Treatment Market by End User, Value (US$ Mn), 2018 - 2031
      • 8.4.1.7. Egypt Actinic Keratosis Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 8.4.1.8. Egypt Actinic Keratosis Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
      • 8.4.1.9. Egypt Actinic Keratosis Treatment Market by End User, Value (US$ Mn), 2018 - 2031
      • 8.4.1.10. Nigeria Actinic Keratosis Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 8.4.1.11. Nigeria Actinic Keratosis Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
      • 8.4.1.12. Nigeria Actinic Keratosis Treatment Market by End User, Value (US$ Mn), 2018 - 2031
      • 8.4.1.13. Rest of Middle East & Africa Actinic Keratosis Treatment Market by Treatment Type, Value (US$ Mn), 2018 - 2031
      • 8.4.1.14. Rest of Middle East & Africa Actinic Keratosis Treatment Market by Disease Type, Value (US$ Mn), 2018 - 2031
      • 8.4.1.15. Rest of Middle East & Africa Actinic Keratosis Treatment Market by End User, Value (US$ Mn), 2018 - 2031
    • 8.4.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. By End User vs By Application Heat map
  • 9.2. Manufacturer vs by Disease Type Heatmap
  • 9.3. Company Market Share Analysis, 2023
  • 9.4. Competitive Dashboard
  • 9.5. Company Profiles
    • 9.5.1. Sun Pharmaceutical Industries Ltd
      • 9.5.1.1. Company Overview
      • 9.5.1.2. Product Portfolio
      • 9.5.1.3. Financial Overview
      • 9.5.1.4. Business Strategies and Development
    • 9.5.2. Biofrontera
      • 9.5.2.1. Company Overview
      • 9.5.2.2. Product Portfolio
      • 9.5.2.3. Financial Overview
      • 9.5.2.4. Business Strategies and Development
    • 9.5.3. Nestle SA
      • 9.5.3.1. Company Overview
      • 9.5.3.2. Product Portfolio
      • 9.5.3.3. Financial Overview
      • 9.5.3.4. Business Strategies and Development
    • 9.5.4. Bausch Health Companies Inc.
      • 9.5.4.1. Company Overview
      • 9.5.4.2. Product Portfolio
      • 9.5.4.3. Financial Overview
      • 9.5.4.4. Business Strategies and Development
    • 9.5.5. Novartis AG
      • 9.5.5.1. Company Overview
      • 9.5.5.2. Product Portfolio
      • 9.5.5.3. Financial Overview
      • 9.5.5.4. Business Strategies and Development
    • 9.5.6. GlaxoSmithKline plc.
      • 9.5.6.1. Company Overview
      • 9.5.6.2. Product Portfolio
      • 9.5.6.3. Financial Overview
      • 9.5.6.4. Business Strategies and Development
    • 9.5.7. Almirall, LLC
      • 9.5.7.1. Company Overview
      • 9.5.7.2. Product Portfolio
      • 9.5.7.3. Financial Overview
      • 9.5.7.4. Business Strategies and Development
    • 9.5.8. LEO Pharma Inc.
      • 9.5.8.1. Company Overview
      • 9.5.8.2. Product Portfolio
      • 9.5.8.3. Financial Overview
      • 9.5.8.4. Business Strategies and Development
    • 9.5.9. Cipher Pharmaceuticals Inc
      • 9.5.9.1. Company Overview
      • 9.5.9.2. Product Portfolio
      • 9.5.9.3. Financial Overview
      • 9.5.9.4. Business Strategies and Development
    • 9.5.10. Pierre Fabre Pharmaceuticals, Inc.
      • 9.5.10.1. Company Overview
      • 9.5.10.2. Product Portfolio
      • 9.5.10.3. Financial Overview
      • 9.5.10.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations
Show more
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Contact Us +1-866-353-3335
Hi, how can we help?
Contact us!